What the Study Found (In Plain English)
Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025), this phase iii randomized trial evaluating 202 human participants investigated: Continuous use of antiangiogenic agents has demonstrated survival benefits in various cancers. Key clinical takeaway: Adding ramucirumab to irinotecan does not provide a significant advantage in OS over irinotecan alone in patients with AGC who have progressed during ramucirumab-containing chemotherapy.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025-07-15; N = 202; Rigor 82/100): Adding ramucirumab to irinotecan does not provide a significant advantage in OS over irinotecan alone in patients with AGC who have progressed during ramucirumab-containing chemotherapy.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.